Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
JNJ-64052781 (duvortuxizumab) is an antibody-like protein that binds to both CD3 and CD19, resulting in cross-linking of tumor B-cells and cytotoxic T-lymphocytes, potentially leading to immune response against B-cell malignancies (NCI Drug Dictionary).
|DrugClasses||CD19 Antibody 16|
|CAS Registry Number||1831098-91-9|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Ibrutinib + JNJ-64052781||Ibrutinib JNJ-64052781||0||1|